RT Journal Article
SR Electronic
T1 Demographic Representation of a Decentralized Long COVID Trial: A Comparison with the 2023 National Health Interview Survey
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.25.24317941
DO 10.1101/2024.11.25.24317941
A1 Sawano, Mitsuaki
A1 Warner, Frederick
A1 Henriquez, Yashira
A1 Bhattacharjee, Bornali
A1 Iwasaki, Akiko
A1 Krumholz, Harlan M.
YR 2024
UL http://medrxiv.org/content/early/2024/11/27/2024.11.25.24317941.abstract
AB Importance Clinical trials can be a chokepoint to progress in medicine. They are commonly expensive, slow, and not participant-centric. Ensuring patient-centric, equitable trials with diverse demographic representation is essential for developing generalizable treatments and reducing healthcare disparities. Thus, there is an urgent need to test new ways of conducting clinical trials. The PAX LC trial is a novel Phase II decentralized, digital, and participant-centric double-blind randomized trial of Paxlovid for long COVID and is a test case for a new approach. There is a need to determine how well the trial enrolled a representative population with long COVID.Objective To compare the demographic characteristics of participants in the PAX LC trial with those reported in the National Health Interview Survey (NHIS) to assess how well the decentralized recruitment reflects the broader population in the US with long COVID.Design Descriptive analysis comparing 2 databases: a Phase 2, 1:1 randomized, double-blind, superiority, placebo-controlled trial conducted in community-dwelling adults with long COVID, and a nationwide observational cross-sectional survey.Setting Decentralized clinical trial with participants recruited from 48 contiguous states in the US. The NHIS survey participants were recruited from all 50 states.Participants 100 highly symptomatic adults with long COVID in the PAX LC trial, compared with 575 from NHIS.Intervention(s) or Exposure(s) None.Main Outcome(s) and Measure(s) Percentage distribution by age group, gender, race and ethnicity, and region for each group.Results PAX LC included 100 participants and NHIS 575, with PAX LC participants being younger (median 42 vs. 53 years). There was an equal proportion of women. Non-Hispanic White representation was higher in PAX LC (89% vs. 61% in NHIS), while the Hispanic and Non-Hispanic Black groups were underrepresented (5% vs. 20% and 1% vs. 12%, respectively). More PAX LC participants were from the Northeast (51% vs. 15%) due to earlier enrollment in this region.Conclusions and Relevance The PAX LC trial highlights the potential of decentralized trials to achieve geographic diversity and balanced age and gender representation. However, to maximize the benefits of this approach, further efforts are warranted to improve racial and ethnic diversity.Trial Registration NCT05668091.Competing Interest StatementIn the past three years, Harlan Krumholz received options for Element Science and Identifeye and payments from F-Prime for advisory roles. He is a co-founder and holds equity in Hugo Health, Refactor Health, and Ensight-AI, Inc., and has research contracts through Yale University with Janssen, Kenvue, Novartis, and Pfizer. Mitsuaki Sawano was partially supported by Polybio and Pfizer. Bornali Bhattacharjee was partially supported by a grant from the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938). Akiko Iwasaki co-founded RIGImmune, Xanadu Bio, and PanV, and is a member of the Board of Directors for Roche Holding Ltd. and Genentech. The other authors report no conflicts of interest.Clinical TrialNCT05668091Funding StatementThis work was supported by funding from Pfizer (Grant #76768419) and from Fred Cohen and Carolyn Klebanoff.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Yale University Institutional Review Board approved the PAX LC study, and the use of NHIS data was exempt from approval, as both datasets are publicly available at the Centers for Disease Control and Prevention website.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymised individual participant data and study documents can be requested from the corresponding author and will be made available 12 months after publication of this paper, subject to the approval of the Trial Steering Committee and funding to anonymise the data.